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Fibroblast growth factor 21 (FGF21) is a liver-derived hormone with pleiotropic
beneficial effects on metabolism. Paradoxically, FGF21 levels are elevated in
metabolic diseases. Interventions that restore metabolic homeostasis reduce
FGF21. Whether abnormalities in FGF21 secretion or resistance in peripheral
tissues is the initiating factor in altering FGF21 levels and function in humans
is unknown. A genetic approach is used to help resolve this paradox. The
authors demonstrate that the primary event in dysmetabolic phenotypes is
the elevation of FGF21 secretion. The latter is regulated by translational
reprogramming in a genotype- and context-dependent manner. To relate the
findings to tissues outcomes, the minor (A) allele of rs838133 is shown to be
associated with increased hepatic inflammation in patients with metabolic
associated fatty liver disease. The results here highlight a dominant role for
translation of the FGF21 protein to explain variations in blood levels that is at
least partially inherited. These results provide a framework for translational
reprogramming of FGF21 to treat metabolic diseases.
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1. Introduction
Fibroblast growth factor 21 (FGF21) a liver-
derived hormone that regulates interactions
between energy metabolism and stress
responses.[1] Understanding the actions of
FGF21 is complicated by species differ-
ences, with most published data coming
from animal models; insights on the ac-
tions of FGF21 in humans are limited. Para-
doxically, despite beneficial effects in ro-
dents, elevated FGF21 levels are reported in
metabolic diseases.[2–5] Consistently, FGF21
is reduced in response to corrective inter-
ventions such as lifestyle modification and
bariatric surgery.[1] Whether abnormalities
in FGF21 secretion or resistance in periph-
eral tissues is the initiating factor behind
these alterations in humans is unknown. As
FGF21 has attracted increasing attention as
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a target for metabolic diseases,[6] clarifying its role in humans is
pivotal.
Leveraging human genomic data is an option to resolve the
FGF21 paradox and to relate the derived information back to
tissue pathology. This is relevant to FGF21 biology for three
reasons. First, circulating FGF21 levels are heritable.[7] Second,
there is large variation in FGF21 levels in healthy subjects, which
is highly unusual for bioactive substances[8] and suggests that
genetic variation in protein synthesis may be important. Third,
studies in humans serve as an “experiment-of-nature,” overcom-
ing species barriers and the limitation of experimental inaccessi-
bility. Further, genetic studies allow for dissection of the sequence
of events that occur at very early time points after the initiation
of metabolic perturbations and the development of FGF21 resis-
tance. Finally, interrogation of genetic data allows the study of
events in the absence of confounding such as by weight gain and
thereby removes (or reduces) the effects of changes in adipose
tissue on FGF21 action. This can permit a more direct investiga-
tion of the mechanisms of FG21 resistance in humans. Studies
through human genetic approaches has been applied to dissect
tissue inflammation, and immunity to infection.[9,10]
Two recent GWAS and subsequent studies have identified
pleiotropic and differential effects for variants at the FGF21 lo-
cus, particularly rs838133. This synonymous SNP (sSNP) located
in the first exon of the gene is associated with dietary macronu-
trient and alcohol intake preferences and various metabolic traits
including hypertension and total body fat.[11–13] Studying FGF21
genotype–phenotype associations therefore provides a unique
opportunity to study the basis of FGF21 resistance in people.
In this work, we first established that the minor allele at
rs838133 mimics the alterations in FGF21 seen in metabolic
diseases. We then provide experimental evidence that increased
FGF21 production induced by altered mRNA translation kinet-
ics is the likely initial perturbation that increases FGF21 levels in
metabolic diseases. We postulate that increased FGF21 induces
peripheral FGF21 resistance, while the latter results in a proin-
flammatory phenotype.
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2.1. Increased Serum Fibroblast Growth Factor 21 in Metabolic
Associated Fatty Liver Disease Is Correlated with Hepatic
Inflammation
To confirm the observation that FGF21 levels are elevated in pa-
tients with metabolic associated fatty liver disease (MAFLD),[14,15]
we assessed its serum levels by enzyme-linked immunosorbent
assay (ELISA) in 410 subjects, including 200 with biopsy-proven
MAFLD and 210 healthy controls. Consistently, an elevation in
FGF21 levels was detected in patients with MAFLD compared
to healthy controls (Figure S1a, Supporting Information). In
addition, circulating FGF21 was elevated in MAFLD patients
with diabetes compared to those without (p < 0.005) (Figure
S1b, Supporting Information). Similarly, there was a correlation
between FGF21 and parameters of glycaemic dysregulation–
blood glucose, as well as with insulin resistance as measured
by HOMA-IR (p < 0.03, for both comparisons, Figure S1c,
Supporting Information).
The elevation in FGF21 levels was more profound with ad-
vanced MAFLD. An elevation in FGF21 levels was detected in
patients with metabolic steatohepatitis compared to those with
simple steatosis (p< 0.001, Figure S1d, Supporting Information).
Similarly, levels were elevated in patients with significant fibrosis
(F2–F4) compared to those with no or mild fibrosis (p < 0.05, Fig-
ure S1e, Supporting Information). In addition, positive and sig-
nificant correlations were observed between FGF21 and liver en-
zymes (AST and GGT) as indices of liver injury (p < 0.005, for
both comparisons, Figure S1f, Supporting Information).
We next analyzed publicly available microarray data of healthy
liver for genes correlated with FGF21 expression (Figure S1g,
Supporting Information). Several genes demonstrated signifi-
cant inverse correlations with FGF21. The inflammatory cy-
tokines and chemokines CXCR4, CXCR6, CXCL12, CCL21, IL18,
IL1R1, IL7, NF-𝜅𝛽 signaling, and the cytokines TNFSF4, TN-
FAIP8L3, C1QTNF1, NFKBIA, PDGFRA and PDGFC all demon-
strated significant inverse correlations.
In sum, while high FGF21 levels are associated with hepatic
inflammation in MAFLD, the opposite is the case in healthy
liver where FGF21 levels negatively correlate with inflammatory
markers. Similar beneficial effects have been reported in murine
data.[16]
2.2. The rs838133 Minor Allele Affects Fibroblast Growth Factor
21 Protein Levels
The FGF21 rs838133 variant has pleiotropic effects on metabolic
traits and dietary macronutrient intake preferences; the func-
tional basis of the genetic association is unknown.[11–13] sS-
NPs are considered silent or invariant for protein function as
by definition they do not alter the amino acid code. However,
there is emerging evidence that sSNPs can change protein lev-
els by altering splicing regulatory sites, local mRNA secondary
structure, mRNA stability, miRNA binding sites, or transla-
tion efficiency.[17,18] Having confirmed that FGF21 is increased
in MAFLD and with liver inflammation, we assessed the im-
pact of FGF21 rs838133 on serum FGF21 levels. Unexpectedly,
the rs838133 (A) allele was significantly associated with higher
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Figure 1. The rs838133 minor allele affects FGF21 protein levels. FGF21 serum levels are elevated in patients carrying the AA genotype compared to
those carrying one or two copies of the (G) allele a) in the initial cohort (n = 200), b) in the validation cohort (n = 211), c) the total cohort (n = 411), and
d) in the healthy cohort (n = 211). e) The changes in serum FGF21 levels between patients with MAFLD (n = 411) and healthy controls (n = 211) was
significant in subjects carrying the (A) allele but not in those with two copies of the (G) allele. Representative liver expression pattern of FGF21 in control
subjects carrying the rs838133 AA and GG genotypes. f) Original magnification: 200×. g) The intensity of FGF21 expression in control subjects carrying
the rs838133 AA and GG genotypes quantified digitally using ImageJ (n = 3, per each group). Statistical differences between groups was assessed by
one-way ANOVA; multiple comparisons were by Bonferroni correction or by t-test, as appropriate (*p < 0.05, ** p < 0.01). The data presented are
mean ± SEM.
serum levels of FGF21 (Figure 1a). This association remained
significant after adjusting for age, sex, body mass index (BMI),
and diabetes (𝛽 ± SE: 173.748 ± 63.449; p = 0.007). This finding
was validated in a second cohort of 211 Italian and Australian pa-
tients with MAFLD (Figure 1b) and in a pooled analysis of both
cohorts (n = 411) (p <0.001, Figure 1c). Similar findings were
observed in healthy controls (n = 211), though it was less pro-
found, with two copies of the (A) allele (AA genotype) required to
have a significant effect (Figure 1d). Collectively, the findings are
consistent with a previous report showing that the rs838145 G-
allele (in high linkage disequilibrium with the rs838133 A-allele)
(r2 = 0.59, D′ = 0.78) is associated with higher fasting levels of
FGF21 in healthy volunteers from the Baltimore Longitudinal
Study of Aging (13).
We next asked whether rs838133 affects the relative change in
FGF21 between healthy and metabolic liver disease subjects. In-
terestingly, the degree of increase in FGF21 protein was signifi-
cant in patients harboring the (A) allele but not in those with the
GG genotype (Figure 1e).
Circulating FGF21 is derived largely from liver;[19] to confirm
this finding in vivo, we examined FGF21 expression according to
rs838133 genotypes by immunohistochemistry. We opted to do
this in the liver of control subjects to minimize the confounding
impact of concomitant liver disease. Consistently, higher levels
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Figure 2. rs838133 minor (A) allele increases FGF21 protein expression via increasing translation efficiency and reducing protein degradation. Huh7
cells stably expressing either the A or G alleles of rs838133 of FGF21 were analyzed. a) Western blot analysis of FGF21 and GAPDH. b) Graph represents
quantification of Western blots with fold change compared to the (G) allele. FGF21 protein level measured by ELISA in c) cell lysate and d) secreted
FGF21 in medium. e) Illustration of the experimental workflow to study translational efficiency. f) qRT-PCR of FGF21 mRNA normalized to GAPDH in the
ribosomal fraction in the A and G alleles. g) ELISA analysis of FGF21 association with active ribosomes in the A and G alleles. Cells were transiently trans-
fected with the G or A allele during the cycloheximide-chase assay. h) Results of one-phase decay after treatment with cycloheximide (CHX, 100 µg mL−1)
for FGF21 in the A and G allele; half-life determinations are shown from three independent transfections (A allele, ≈129.7 min, G allele, ≈31.48 min).
i)Huh7 cells stably expressing the A and G alleles of rs838133 of FGF21 were analyzed for stability of FGF21 mRNA. Cells were treated with actinomycin
D to arrest new transcription and is presented as mRNA remaining over time relative to that at 0 h set as 100%. Half-life (50% mRNA remaining [dashed
line]): A allele, 30.52 min; G allele, 27.46 min. Values of three independent replicates are represented by vertical bars and are mean ± SEM; *p < 0.05
using the student t-test.
of FGF21 protein was found in the liver of people carrying the
minor (A) allele compared to those homozygous for the major
(G) allele (Figure 1f,g, p = 0.0001).
In total, the rs838133 minor (A) allele is associated with higher
hepatic FGF21 protein levels in healthy controls and in patients
with metabolic disease (MAFLD), though its impact is more pro-
found in the latter.
2.3. The rs838133 Minor Allele Increases Hepatic Fibroblast
Growth Factor 21 Protein by Increasing Translation
Studying FGF21 genotype–phenotype associations can provide
an opportunity to study the consequences of allelic alterations
in the genome. To address this, we developed Huh7 cell lines
that stably express FGF21 isoforms representing the two alleles
(A/G) of rs838133. We then examined if the isoforms influence
steady-state FGF21 protein levels. Interestingly, protein expres-
sion of the FGF21 minor (A) allele-expressing cells was increased
25–30% by Western blot (Figure 2a,b, p < 0.5) and by ELISA
of both cell lysates (Figure 2c, p < 0.05) and secreted FGF21
in the medium (Figure 2d, p < 0.05) relative to the major (G)
allele. These data provide experimental evidence that increased
FGF21 production might initiate FGF21 resistance in a genotype-
dependent manner.
We next tried to understand the mechanisms of increased
FGF21 production in those harboring the minor allele of
rs838133. Four steps contribute to protein abundance, namely
transcription, mRNA degradation, translation, and protein degra-
dation. Several reports suggest that protein abundance is
Adv. Sci. 2021, 2004168 © 2021 The Authors. Advanced Science published by Wiley-VCH GmbH2004168 (4 of 16)
www.advancedsciencenews.com www.advancedscience.com
predominantly regulated at the level of translation and to a lesser
extent by transcription,[20,21] while mRNA and protein degra-
dation each only accounts for 5–8% of the variance in protein
levels.[22] If the rate for one of these steps differs markedly in
relation to the others, it would be the dominant mechanism de-
termining variations in protein abundance.[23] Hence, we queried
these steps to explore the impact of the sSNP rs838133 on FGF21
protein levels.
As demonstrated in Figure S2a, Supporting Information, no
difference was observed in the steady-state mRNA expression
level between both alleles of rs838133. Next, we examined if the
rs838133 variant alters FGF21 mRNA allele-specific expression
(a method that identifies subtle differences in the effects of vari-
ants on gene expression and transcript levels[24]) in 13 human
liver samples from subjects harboring the rs838133 heterozy-
gote genotype. Again, no significant rs838133 allelic differences
in FGF21 gene expression was observed (p = 0.3, Figure S2b,
Supporting Information). This result is consistent with previ-
ous observations which report no association between the FGF21
rs838133 allele and FGF21 expression quantitative trait loci in the
liver based on 1031 samples.[11]
Some sSNPs may alter mRNA splicing by changing the reg-
ulatory motifs of exonic splice enhancers.[25] To determine if
rs838133 affects FGF21 mRNA splicing, we queried the exonic
splicing enhancer finder. This revealed that the rs838133 SNP
was not predicted to induce any detectable alternative splicing
product above the background of the major-type allele (Figure
S2c, Supporting Information). In total, these observations imply
that rs838133 does not affect FGF21 mRNA level or splicing.
The observed increase in protein with similar mRNA lev-
els between rs838133 alleles raised the intriguing possibility
that this variant regulates the translation rate. To test this, we
employed L-azidohomoalanine (AHA)-mediated Ribosome iso-
lation (AHARIBO) in the two FGF21 allele cell lines. This novel
methodology examines for active translation based on the in-
corporation of the non-canonical amino acid AHA followed by
sBlock treatment to stabilize the AHA-labeled peptides on ribo-
somes. Active ribosomes and their interactome (RNAs or pro-
teins) are purified by magnetic beads targeting the azido groups
incorporated in the nascent chains[26] (Figure 2e). Subsequently,
mRNAs were extracted from both the ribosomal fractions and the
total lysates and used for the relative quantification of FGF21 lev-
els using quantitative polymerase chain reaction (qPCR) with the
same set of FGF21 probes. Remarkably, the normalized fraction
of FGF21 transcripts associated with active translating ribosomes
was higher by eightfold in the minor (A) compared to the major
(G) allele (Figure 2f).
Then, to estimate if the impact of rs838133 on translation rate
would affect FGF21 protein associated with translationally active
ribosome levels, we applied the same methodology as above and
the protein was isolated. Interestingly, FGF21 protein levels were
higher by approximately threefold in the (A) allele compared with
that of the (G) allele (Figure 2g).
In addition, we identified NCBI Gene Expression Omnibus
(GEO) databases (GEO: GSE32504 and GSE39036) that contain
transcriptomic and genotype profiles of 148 liver samples of
Caucasian origin. Transcriptomic data was processed via R soft-
ware including quantile normalization and log2 transformation.
Consistently, volcano plot and gene set enrichment analysis
(GSEA) between the (A) allele and GG genotype samples showed
overrepresentation of gene levels in translation pathways in
the (A) allele (Figure S3, Supporting Information), including
translation initiation and translational regulation, cotranslation,
and ribosomal proteins. In total, these results demonstrate that
the minor (A) allele of rs838133 increases FGF21 translation
and hence synthesis.
2.4. The rs838133 Minor Allele Increases Protein Stability
Protein expression is determined by both production and degra-
dation. In addition to regulating the sensitivity of FGF21 re-
sponses, FGF21 activity could also be regulated by alterations
in its stability or half-life. We thus examined whether rs838133
affects FGF21 protein degradation. To this end we assessed the
stability of the protein in the presence of the protein synthesis
inhibitor, cycloheximide. To minimize the likelihood that differ-
ent total amounts of protein influence half-life calculations, cells
were transiently transfected with the rs838133 minor (A) and
rs838133 (G) allele plasmids. This allowed for total protein abun-
dance to be equal between the two alleles at the beginning of the
cycloheximide-chase experiment (Figure S4a, Supporting Infor-
mation, by Western blot and Figure S4b, Supporting Informa-
tion, by ELISA). Consistent with the increased steady-state ex-
pression, the minor (A) allele exhibited a significantly reduced
rate of degradation (t1/2 ≈ 129.7 min) compared with the major
(G) allele (t1/2 ≈ 31.48 min) (Figure 2h).
We also investigated other factors that could contribute to al-
lelic differences in FGF21 protein abundance apart from FGF21
protein degradation. Since mRNA stability may impact protein
abundance,[27] we measured the half-life of mRNA of both alle-
les after treatment of the stably transfected Huh7 cell lines with
actinomycin D, a potent transcription inhibitor. No difference be-
tween the half-lives of both alleles was observed (Figure 2i). The
results were identical in an analogous experiment using a tran-
sient transfection model of both FGF21 alleles (data not shown).
In total, these results indicate that the rs838133 minor allele
elicits significant increases in protein stability in human hepatic
cells and consequently influences FGF21 homeostasis.
2.5. The rs838133 Minor Allele Has Higher Codon Usage
Since rs838133 impacts translation efficiency, protein synthe-
sis, and FGF21 stability, we investigated for the mechanisms
by which the translational rate is altered in an rs38133 allele-
specific manner. To do this we investigated for factors that in-
fluence translation kinetics. First, we considered relative synony-
mous codon usage (RSCU) and calculated the RSCU values of
glycine encoding codons in the entire human genome and solely
within the FGF21 CDS (Table S1, Supporting Information). This
analysis revealed that codon usage is biased toward the minor al-
lele (A) which is over-represented (RSCU> 1.6) in a gene-specific
manner. This indicates that translation elongation of FGF21 is
faster in cells with the rs838133 (A) allele.
Given that synonymous variants are implicated in alter-
ing mRNA structure and the latter can affect translation
efficiency,[28,29] we utilized three different algorithms to predict
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changes in the RNA structure induced by rs838133. These
included the RNAfold WebServer (compares the influence of
the variant on the secondary structure of the gene),[30] RNAsnp
(provides a p-value reflecting significance of local structure
base-pairing distance),[31] and MutaRNA (provides a collection
of measures and visualizations for an intuitive interpretation
of the impact of variants on the RNA secondary structure).[32]
The three algorithms consistently revealed that rs838133 causes
significant secondary structure changes and weak secondary
structures within mRNAs in the (A) allele that can accelerate
translation[33] (Figure S5, Supporting Information).
2.6. RPLP0 Abundance Determines Effects of rs838133 on the
Translation Efficiency
We investigated other mechanisms by which the translation rate
can be altered in an rs838133 allele-specific manner. Transfer ri-
bonucleic acid (tRNA) is a small ribonucleic acid (RNA) chain
(74–93 nucleotides) that transfers a specific amino acid to a grow-
ing polypeptide chain at the ribosomal site of protein synthe-
sis during translation. tRNA abundance is a major determinant
of ribosome speed at a codon.[34] Thus, we measured tRNA lev-
els using nrStar Human tRNA PCR Arrays that profile 185 hu-
man tRNAs (163 nuclear tRNA isodecoders and 22 mitochondrial
tRNA species) covering all the nuclear anticodon isoacceptors cat-
alogued in GtRNAdb and providing insights on both the isoac-
ceptor and the specific isodecoder expression in the Huh7 cells
expressing the two allelic variants. Using t-distributed stochastic
neighborhood embedding (t-SNE), we found that the tRNAs can
be clearly segregated into three clusters (C1, C2, and C3) (Fig-
ure 3a). The distribution of tRNAs among the three clusters cor-
responded to key functional features. C1 is enriched in mitochon-
drial tRNA while C2 contains increased levels of tRNA for the
uncharged group. In contrast, C3 has more charged tRNA with
the increase in the tRNA for the uncharged group being less pro-
nounced. These observations indicate that the tRNA pool is re-
arranged according to the FGF21 allelic variant that influences
translation.
To further investigate the basis of this change in the tRNA pool,
a human reverse transcription-quantitative polymerase chain re-
action (RT-qPCR) array was used to screen cells stably expressing
the two FGF21 alleles for differential abundance in transcription
of 28 tRNA associated genes. Interestingly, this analysis revealed
that ribosomal protein lateral stalk subunit P0 (RPLP0) abun-
dance increased substantially in the minor (A) allele-expressing
cells, while other genes levels were unchanged between the two
groups samples (Figure 3b). Analysis of GEO: GSE39036 data
confirmed that RPLP0 is upregulated in the (A) allele compared
to the GG genotype, with no differences in other genes (Fig-
ure 3c). The human ribosomal P complex consists of the acidic
ribosomal P proteins and includes in addition to RPLP0, both
RPLP1, and RPLP2 (RPLP proteins). Therefore, we investigated
for these three RPLP proteins in the stable expressing cells of
rs838133 alleles using reverse transcriptase-polymerase chain re-
action (RT-PCR). This confirmed increases in RPLP0 in the mi-
nor (A) allele-expressing cells, while there was no difference in
expression of the other RPLP proteins, RPLP1 and RPL2 (Fig-
ure 3d), with similar data in the GEO dataset.
Next, we investigated for the differential expression pattern of
RPLP0 in the translating ribosomes from stably expressing cells
of the (A) and (G) alleles. Remarkably, the normalized fraction of
RPLP0 transcripts associated with active translating ribosomes
was higher by ≈60-fold in the (A) compared to the (G) allele
(Figure 3e).
Hence, the robust and unique enrichment of RPLP0 levels
in the (A) allele caught our interest and we opted to determine
whether suppression of RPLP0 by specific siRNA would influ-
ence tRNA levels, translation kinetics, and FGF21 levels in hu-
man hepatocytes stably expressing the rs838133 minor (A) and
rs838133 (G) alleles. In samples transfected with RPLP0-directed
siRNA, RPLP0 mRNA levels were reduced by ≈80%, with no
change in other RPLP proteins (RPLP1 and RPL2) (Figure S6a–
c, Supporting Information), and no cell toxicity was observed. In-
terestingly, RPLP0 silencing changed the tRNA profile in cells ex-
pressing the (A) allele, restoring it to comparable levels to the (G)
allele (Figure 3f). In addition, RPLP0 silencing decreased FGF21
protein in cells expressing the (A) allele, restoring it to compa-
rable levels to the (G) allele in the cell lysate (Figure 3g) and in
FGF21 levels in the medium (Figure 3h). However, RPLP0 si-
lencing, only modestly enhanced FGF21 mRNA expression by
≈1.4-fold. The latter is likely a feedback mechanism suggesting
that the effect of RPLP0 on FGF21 is mainly on translation (Fig-
ure S6d, Supporting Information). To confirm this, we analyzed
whether RPLP0 suppression reduces FGF21 protein associated
to translationally active ribosomes levels using the AHARIBO
method. Consistently, RPLP0 silencing decreased total FGF21
protein in cells expressing the (A) allele to comparable levels to
that of the (G) allele (Figure 3i). We conclude that the RPLP0 de-
pletion effect is primarily through effects on translation and an
altered tRNA profile.
2.7. The rs838133 Minor Allele Does Not Affect Fibroblast
Growth Factor 21 Receptor and Fibroblast Activation Protein
Levels
FGF21 acts on a cell surface receptor complex comprised of two
proteins: a conventional tyrosine kinase FGF receptor (FGFR)
and a coreceptor protein, 𝛽-klotho (KLB). FGF21 preferentially
binds and activates the FGFR1 that is predominantly expressed
in adipose tissue and adipocytes.[35] The notion of “FGF21 resis-
tance” is the widely proposed explanation for increases in circu-
lating FGF21 levels in metabolic diseases.[36] In this model, the
increase in FGF21 is caused by a downregulation of expression of
its receptors (or desensitization) mainly in white adipose tissue,
resulting in compensatory FGF21 production.
Thus, to provide a comprehensive evaluation of the basis of
FGF21 abnormalities in metabolic disease, we analyzed the as-
sociation between rs838133 and the expression of molecular ac-
tors of FGF21 responsiveness (FGFRs and KLB) in liver and adi-
pose tissue. There was no evidence that this variant is associated
with KLB gene expression in the healthy liver based in the hu-
man Genotype-Tissue Expression (GTEx) database; this was con-
firmed using the GEO dataset (Figure 4a). Similarly, no differ-
ence was observed in steady-state KLB mRNA expression levels
between both stably expressing cells of the two alleles of rs838133
(Figure 4b). In addition, this variant was not associated with KLB
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Figure 3. RPLP0 abundance determined effects of rs838133 on translation efficiency. a)Multivariate analysis of the tRNA expression patterns using t-SNE.
Three groups of tRNAs (C1, C2, and C3) are highlighted. b)Heatmap of quantification of change in abundance of transcription of 28 tRNA-associated
genes in Huh7 cells stably expressing the A and G alleles of rs838133 of FGF21 analyzed by TaqMan Array and in GEO: GSE32504 and GSE39036,
respectively. This showed a unique upregulation in RPLP0 in A allele-expressing cells c) that was confirmed by RT-PCR, d) with no changes in other RPLP
proteins (RPLP1 and RPLP2). e) The normalized fraction of RPLP0 transcripts associating with actively translating ribosomes was higher in the minor
(A) allele compared to the major (G) allele. f) Hierarchical clustering of tRNAs based on their relative changes in abundance upon RPLP0 inhibition
by siRNA. RPLP0 inhibition by siRNA decreases FGF21 protein level measured by ELISA g) in cell lysates and h) secreted in medium and i) in active
ribosomes in the (A) allele cells restoring it to levels comparable to that in (G) cells. Values of three independent replicates are represented by vertical
bars and are mean ± SEM; *p < 0.05 using the student t-test or one-way ANOVA; multiple comparisons were by Bonferroni correction, as appropriate.
expression in adipose tissue in the GETEX database (Figure 4c).
For further confirmation, we evaluated circulating KLB in 200
patients with MAFLD and in 44 healthy individuals. Circulat-
ing KLB concentration was not different between patients with
MAFLD and healthy controls (p > 0.5; Figure 4d). Consistently,
in patients with MAFLD, KLB levels were not different according
to rs838133 genotype (p > 0.3; Figure 4e). Similarly, this variant
was not associated with FGFR1 gene expression in adipose tissue
(Figure 4f).
Human FGF21 is inactivated by fibroblast activation protein
(FAP),[35] so we also examined the association between rs838133
and FAP levels. As depicted in Figure 4g, this variant was not
found to be associated with FAP gene expression in the liver in
both the GTEx database and the GEO dataset, or in adipose tis-
sue in the GTEx database (Figure 4h). To verify this finding, we
measured circulating FAP in 200 patients with MAFLD and 44
healthy individuals. Circulating FAP concentration was higher in
patients with MAFLD compared to controls (p< 0.001; Figure 4i).
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Figure 4. The rs838133 minor allele does not affect FGF21 receptor and FAP levels. a) rs838133 is not associated with KLB gene expression in the
liver based on the Genotype-Tissue Expression (GTEx) data and the GEO dataset (GEO: GSE32504 and GSE39036). b) No difference was observed in
steady-state KLB mRNA expression levels between stably expressing cells of the two alleles of rs838133. c) This variant was not associated with KLB gene
expression in adipose tissue from the GTEx database. Circulating KLB concentration was not significantly different between patients with d) MAFLD
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In patients with MAFLD, FAP serum levels were not associated
with rs838133 (p > 0.8; Figure 4j).
Finally, to investigate if the receptors are equally activated with
FGF21 that issues from either the G or A allele, we assessed for
FGF21 signaling in both A and G stably expressing cell lines by
measuring the FGF21 downstream signaling proteins pERK and
pAKT and the expression of Egr1 and cFos, as recommended
as the criteria for defining the term “FGF21 resistance."[37] As
shown in Figure S7, Supporting Information, we did not observe
any differences between A and G stably expressing cell lines.
In total, this data suggests that despite genotype dependent in-
creases in FGF21 protein production, there is no alteration in
FGF21 responsiveness (FGFRs and KLB) in liver or adipose tis-
sue or in FGF21 activity.
2.8. The rs838133 Minor Allele Increases the Risk of Hepatic
Inflammation in Metabolic Associated Fatty Liver Disease
To relate our findings back to tissues outcomes, we assessed
the association of rs838133 with hepatic inflammation. Though
FGF21 rs838133 shows a pleiotropic effect on various metabolic
traits,[11–13] the role of this variant in MAFLD is unknown.
Shared risk variants between metabolic diseases are increasingly
recognized.[38,39] Thus, we genotyped the FGF21 rs838133 vari-
ant in a cohort of individuals (n= 1209) with histologically proven
MAFLD. Baseline characteristics of the cohort are summarized
in Table S2, Supporting Information. FGF21 rs838133 was con-
firmed to be in Hardy–Weinberg equilibrium and showed a mi-
nor allele frequency of 0.43 in our cohort, similar to that observed
in other European populations, (http://browser.1000genomes.
org). The association of rs838133 genotype with the spectrum of
liver damage related to MAFLD is shown in Figure 5a.
In this analysis, the minor (A) allele was associated with se-
vere hepatic inflammation (p = 0.003) using an additive model.
The effect was more profound when the cohort was dichotomized
into absent (0) versus any inflammation (A1–A3) (p = 0.0001) or
when adopting a dominant model that compared the presence of
any inflammation (Odds ratio [OR]: 1.77; 95% confidence interval
[CI]: 1.34–2.33, p = 0.0001). The association with inflammation
remained significant after adjusting for age, gender, BMI, and
type 2 diabetes mellitus (OR: 1.67, 95% CI: 1.29–2.16, p= 0.0001).
The (A) allele was also associated with severe inflammation (A2–
A3) (OR: 1.32; 95% CI: 1.01–1.71, p = 0.04). A similar trend
was observed with the severity of ballooning though this was not
significant (p = 0.069). No association was observed with either
steatosis or fibrosis. No differences in clinical, anthropometric,
or biochemical indices including aminotransferases were found
between the FGF21 rs838133 genotypes.
2.9. The rs838133 Minor Allele Has Differential Effects on
Inflammation in Hepatocytes In Vitro and In Vivo
Based on the above data, we explored the functional impact of
rs838133 on inflammation using Huh7 cells that stably express
the two FGF21 alleles. In this analysis, the rs838133 (A) allele-
expressing cells had lower induction of mRNA levels of key cy-
tokines and chemokines including monocyte chemoattractant
protein-1 (MCP-1/CCL2), chemokine (C-X-C motif) ligand 10
(CXCL10), and tumor necrosis factor alpha (TNF-𝛼) in response
to stimulation of the toll-like receptor 4 (TLR4) by lipopolysac-
charide (LPS) (Figure 5b) or palmitate and oleate (Figure 5c)
(p < 0.05). These findings are in line with the known anti-
inflammatory effects of FGF21.
Our in vivo results were opposite when comparing the liver
expression of inflammatory markers in MAFLD patients carrying
either the rs838133 (A) or (G) genotype allele. Consistent with the
earlier genetic findings, we found enhanced expression of these
markers in the liver of patients harboring the (A) allele compared
to those carrying the (G) allele (p < 0.05, n = 11) (Figure 5d).
Consistently, GSEA between (A) allele and GG genotype samples
in the GEO database shows overrepresentation of gene levels in
inflammation pathways in the (A) allele (Figure 5e), including
inflammatory response, TNF-𝛼 signaling, NFK𝛽 signaling, and
interferon gamma responses. Finally, we investigated the role of
rs838133 on the regulation of hepatocyte lipid droplet content. As
shown in Figure S6a,b, Supporting Information, no difference in
intracellular triglyceride content was noticed with palmitate and
oleate treatment in cell lines overexpressing either the FGF21 A
or G alleles.
3. Discussion
The nutritional regulation of FGF21 is complex and liver
FGF21 production appears to be stimulated by an imbalance
in macronutrient intake. In particular, circulating FGF21 levels
are markedly increased by diets that are high in carbohydrate
but low in protein, as well as by alcohol consumption.[40–42] In
contrast, exogenous FGF21 treatment reduces the consumption
of sweet foods and alcohol, and increases the consumption of
protein.[41] In people, several large genetic studies have shown
that the rs838133 minor (A) allele is associated with higher sugar
and alcohol intake and lower protein intake.[11] Our findings sug-
gest that the metabolic stress induced by a high sugar and low
protein western type diet in the (A) allele carriers might trigger
the high FGF21 levels we observed. Despite genotype dependent
increases in FGF21 protein production, there is no alteration in
FGF21 responsiveness (FGFRs and KLB) in liver or adipose tis-
sue or in FGF21 activity. This implies that an early and perhaps
primary event in FGF21 alterations with the onset of human
metabolic diseases is increasing genotype-dependent FGF21 pro-
duction rather than decreased peripheral tissue sensitivity. This
might be mediated by RPLP0-tRNA-dependent remodeling of the
stress-induced translatome as an adaptive response to suppress
the ingestion of simple sugars, while stimulating protein intake.
However, further increases in FGF21 with progressive metabolic
morbidity could then lead to an imbalance between FGF21 and its
occupied receptors leading to impairment of FGF21 downstream
(n = 200) and healthy individuals (n = 44), or e) according to rs838133 genotype in patients with MAFLD. f) rs838133 is not associated with FGFR1 gene
expression in adipose tissue from the GTEx database. rs838133 is not associated with FAP gene expression in the liver in g) both the GTEx database and
the GEO dataset or in h) adipose tissue. i) Circulating FAP concentration was higher in patients with MAFLD (n = 200) compared to controls (n = 44).
j) In patients with MAFLD, FAP serum levels were not associated with rs838133.
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Figure 5. The rs838133 minor allele impacts the acquisition of a proinflammatory phenotype in hepatocytes. a) Histological features were evaluated
in a large cohort of biopsy-proven patients with MAFLD (n = 1209). GG, homozygotes for the G allele; GA, heterozygotes; AA, homozygotes for the A
allele. Numbers per each genotype are presented under the figure. Genetic analyses were calculated by using an additive model; p-values represent the
significance for trend in the prevalence of more severe degrees of histologic damage among the genotypes. Huh7 cells stably expressing the A allele
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signaling (Figure 5f). Whether this effect is tissue specific or a
generalized effect is yet to be determined.
In line with our hypothesis, a recent study employed a tissue-
specific 𝛽-klotho transgenic mouse and showed that FGF21
resistance is not mediated by downregulation of 𝛽-klotho ex-
pression in white adipose tissue.[43] Similarly, another report
demonstrated lack of obvious FGF21 resistance in two mouse
models of obesity and insulin resistance, viz ob/ob and diet-
induced obese mice.[44] Furthermore, a time-course study in
the heart over 12 weeks after high fat diet feeding demonstrated
that increase in plasma FGF21 levels precedes impairment of
cardiac FGF21 signaling pathways, including FGFR1, 𝛽-Klotho,
p-ERK1/2, p-Akt, and PGC-1𝛼 expression.[45]
It is noteworthy that similarly for insulin resistance, its sig-
naling pathway has been investigated in detail and two points of
view are reported. The classic dogma is that lack of sensitivity in
peripheral tissue raises blood-glucose levels, which in turn stimu-
lates insulin hypersecretion. However, on the basis of numerous
observations challenging this traditional paradigm, counter argu-
ments have emerged that postulate the reverse. In this scenario,
hyperinsulinemia is the initial and primary abnormality in obe-
sity which drives subsequent insulin resistance.[46] This notion
is supported by a variety of experimental data including that af-
ter high fat diet feeding regimens in both murine and human
subjects, in which elevated fasting levels of circulating insulin
and not glucose, is the initial event.[46] In addition, it is com-
monly recognized that some people with long-established obesity
demonstrate fasting hyperinsulinemia despite showing no signs
of excess blood-glucose concentrations that would theoretically
be required to promote insulin secretion.[47,48]
Cells dynamically adjust their protein translation profile to
maintain homeostasis in the context of changing environmental
cues. During nutrient and metabolic stress, the eukaryotic trans-
lation initiation factor 2a kinase, general control non-depressible
2 (GCN2) is activated to elicit a homeostatic response, called
the integrated stress response (ISR).[49] Acute/transient stress
is characterized by decreased global protein synthesis and in-
creased upstream open reading frame (uORF) mRNA transla-
tion. Following resolution of the ISR, normalization of protein
synthesis occurs.[49] However, during chronic metabolic stress,
the chronic ISR program is characterized by persistently elevated
uORF mRNA translation, with the vast majority (98%) of mR-
NAs which were translationally upregulated during the acute ISR
remaining translationally active.[50] ISR activation has been ob-
served in metabolic diseases including MAFLD.[51] In the liver, it
has been shown that ISR activation in response to diverse phys-
iological or pathological stressors such as starvation, results in a
dramatic induction of FGF21.[52–54] In this context, a direct and
pivotal role for RPLP0 in propagating the signal from ribosomes
perturbed by nutrient stress (amino acid starvation) to GCN2 and
ISR activation has been recently reported, without affecting the
endoplasmic reticulum unfolded protein stress-induced ISR.[55]
In addition, previous data indicates that although RPLP0 phos-
phorylation is not required for overall ribosome activity, it may
affect the translation of specific proteins, those mainly involved
in metabolic processes.[56] In total, our data suggests that RPLP0
could be the link between nutrient stress, t-RNA profile, trans-
lational rate, and increased FGF21 levels in metabolic disorders
and is regulated at the gene level. In this scenario, reduced down-
stream FGF21 signaling and activity would be a secondary adap-
tive response in dysmetabolic states. Further studies would be re-
quired to clarify the detailed mechanisms of RPLP0 upregulation
of the FGF21 A allele and the effects on FGF21 levels.
Linking our findings back to tissues, our data implies a mech-
anistic connection between presence of the (A) allele, elevated
FGF21, and an inflammatory phenotype under metabolic stress.
We confirm a role for FGF21 as a component of the milieu con-
tributing to steatohepatitis, with the inflammatory phenotype
likely representing FGF21 resistance. Interestingly, we demon-
strated a differential response for the rs838133 (A) allele in vitro
and under metabolic stress in vivo, further supporting our pro-
posed model.
Due to the pleiotropic and multi-organ metabolic actions of
FGF21 and emerging evidence that this hormone mediates the
therapeutic effects of currently available drugs and those under
development for treatment of metabolic diseases, FGF21 has at-
tracted great interest as a therapeutic target for disorders such
as obesity, type 2 diabetes, MAFLD, atherosclerosis, and car-
diovascular diseases.[2–5] Intriguingly, our data suggests that ap-
proaches to mildly reduce FGF21 production could be a novel and
more efficient strategy to treat obesity and metabolic disorders.
This could be achieved via targeting its translational reprogram-
ming to allow precise tuning of protein synthesis rates. The levels
of circulating FGF21 necessary to mediate beneficial metabolic
effects without bone toxicity[57] is around 25–50 ng mL−1, inde-
pendent of the target organ. This is much lower than the peak
concentrations achieved in clinical trials after periodic admin-
istration of FGF21 analogues at supraphysiological doses.[58,59]
Consistently, some recent studies show that modulation of the
translation velocity could be a better therapeutic strategy for
the treatment of cystic fibrosis mutants and for some types of
cancers.[60,61] Further studies would be required to determine the
feasibility and safety of this therapeutic approach.
Finally, our data argues for the importance of the incorpora-
tion of an individual’s genome composition information in clini-
cal trial ecosystems and drug development. This would allow for
had lower levels of TNF-𝛼, CCL2, and CXCL10 in response to b) TLR4 (LPS, 500 ng) or c) palmitic acid and oleate (200 and 400 um, respectively) after
24 h challenge, compared to the G allele (n = 3). d) Comparison between hepatic expression of inflammatory markers between subjects carrying the
(A) allele (n = 7) or (GG) homozygous genotype (n = 3) shows that the minor allele (A) carriers express higher proinflammatory markers (TNF-𝛼,
CCL2, and CXCL10). e) Gene set enrichment analysis (GSEA) analysis for the NCBI Gene Expression Omnibus (GEO) database (GEO: GSE32504 and
GSE39036) that contains transcriptomic and genotype profiles, respectively, of 149 liver samples of Caucasian origin subjects shows over-representation
of genes encoding inflammatory pathway in the (A) allele versus those with two copies of the (G) allele. f) Proposed model for the functional effects for
the synonymous single nucleotide polymorphism rs838133 via mistranslation and alteration of protein abundance. mRNA expression was analyzed by
real-time PCR and normalized to GAPDH. Data are represented by vertical bars and are mean ± SEM; *p < 0.05 using the student t-test. Abbreviations:
TNF𝛼, tumor necrosis factor alpha; C–X–C motif chemokine 10 (CXCL10) also known as interferon 𝛾-induced protein 10 kDa; Chemokine CCL2 (also
known as monocyte chemoattractant protein-1, MCP-1).
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improved characterization of the target population that would
benefit from FGF21 treatment and ensures that the interven-
tion is equally effective across different populations. Such an ap-
proach requires moving from traditional one-phase, one-drug,
one-indication clinical trials to novel trial platforms that use mas-
ter or basket protocols.[62]
In conclusion, we identified an unanticipated mechanism that
helps to reconcile the apparently contradictory reports regard-
ing the significance of elevations in FGF21 in the context of
metabolic diseases. Our results suggest that the primary event
in dysmetabolic states is an initial elevation of FGF21 secretion
by translational reprogramming in a genotype and context spe-
cific manner. The upregulated FGF21 then induces FGF21 resis-
tance, for example, in white adipose tissue, as a beneficial rather
than a pathological adaptation to inhibit FGF21 signaling. An
important next step will be to determine whether elevations in
FGF21 are coupled to specific changes in FGF21 receptors or to
factors binding to the receptors that render it less efficacious fol-
lowing repeated stimulation, and how it can be best targeted to
treat metabolic diseases.
4. Experimental Section
Plasmids: Transfection was performed with FuGENE HD (Promega)
according to the manufacturer’s instructions. pcDNA3.1 constructs con-
taining the full-length human FGF21 with genetic variation corresponding
to A or G (of rs838133) were used for in vitro transcription and translation
experiments as described previously.[28,29] Development of cell Lines ex-
pressing rs838133 was done using antibiotic selection. All constructs used
in these studies were sequenced prior to experiments.
SiRNA: Transfection was performed with Lipofectamine RNAiMAX
(Invitrogen) according to the manufacturer’s instructions using 75 nm
of ON-TARGETplus human RPLP0 siRNA smart-pool or ON-TARGETplus
Non-targeting pool as a control for 48 h.
Ribonucleic Acid Extraction, First-Strand Complimentary Deoxyribonucleic
Acid Synthesis: Total RNA was extracted from tissue and cell lysates using
the Qiagen RNeasy Kit according to the manufacturer’s instructions. Com-
plimentary DNA (cDNA) was reverse transcribed from total RNA using
qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD, USA)
according to the manufacturer’s instructions.
Real-Time Quantitative Polymerase Chain Reaction: Real-time PCR was
performed on Applied Biosystems, Foster City, CA, USA, using TaqMan
Fam-labeled expression probes with TaqMan Fast Advanced Master Mix
or forward and reverse primers for each gene of interest with SYBR Select
Master Mix and were normalized to the expression of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Expression was measured using CT
values normalized to that of GAPDH (ΔCT = CT [GAPDH] − CT [target])
and then expressed as 2−ΔCT. Primers sequences and expression probe
IDs were provided in key resource table.
Allele-Specific Expression: To explore whether rs838133-allele-specific
expression contributes to FGF21 liver expression, the authors quantified
both liver complimentary DNA (cDNA) and genomic DNA (gDNA) from
13 patients heterozygous for the variant using real-time quantitative RT-
PCR.
Enzyme-Linked Immunosorbent Assay: Concentrations of human
FGF21, KLB, and FAP were quantified according to the manufacturer’s
instructions by using ELISA kits.
Liver Immunohistochemistry: 4 𝜇m sections were mounted onto
saline-coated glass slides to ensure section adhesion through subsequent
staining procedures. Slides were stained using the BOND RX Fully Auto-
mated Research Stainer (Leica Biosystems) using the Bond Polymer Refine
Detection Method Algorithm as per manufacturer instructions (DS9800
Leica). The slides were incubated with a dilution of 1:200 rabbit mono-
clonal antibody against human anti-FGF21 (FGF21 antibody [MA532652]
size 100 UL, Invitrogen). Negative controls were carried out with rabbit
serum diluted to the same concentration as the primary antibody. The ex-
tent of FGF21 immunostaining was assessed using ImageJ.
Western Blot: Whole cell extracts were fractionated by SDS-PAGE and
transferred to a polyvinylidene difluoride membrane using a transfer appa-
ratus according to the manufacturer’s protocol (Bio-Rad). Following trans-
fer, membranes were blocked with 5% non-fat milk in TBST (50 mm Tris,
pH 7.4, 150 mm NaCl, 0.05% Tween-20) for 1 h at room temperature.
Membranes were washed twice with TBST and incubated with primary an-
tibodies diluted in 5% skim milk/TBST, overnight at 4 °C. Following incu-
bation, membranes were washed thrice for 10 min with TBST and incu-
bated with secondary antibodies, diluted in 5% skim milk/TBST, for 1 h
in dark. Blots were washed with TBST thrice and developed with Super-
Signal West Pico PLUS Chemiluminescent and SuperSignal West Femto
Maximum Sensitivity Substrates (Life Technologies, Australia) according
to the manufacturer’s protocol. Membranes were scanned using Chemi-
Doc Touch Imaging system (Bio-Rad).
Immunoprecipitation of Fibroblast growth factor 21 with Active Ribosomes:
Huh7 cell lines that stably expressed FGF21 isoforms representing the
two alleles (A/G) of rs838133 (with or without SiRNA transfection) were
treated with L-leucine for 40 min then lysed and active ribosomes were
isolated using the AHARIBO_Protein and AHARIBO_RNA kits (Immag-
ina Biotechnology). Then, RNA and proteins associated to the active ri-
bosomes were extracted directly from beads according to manufacturer’s
instructions.[26] Following the isolation, RNA was reverse transcribed and
amplified by RT-PCR; proteins were resolved and subject to ELISA, as de-
scribed above.
Measurement of Fibroblast Growth Factor 21 Protein Stability: To assess
the impact of rs838133 polymorphisms on the rate of FGF21 degradation,
Huh7 cells were transfected with pcDNA3.1 constructs containing the full-
length human FGF21, with genetic variation corresponding to A or G (of
rs838133) using FuGENE HD (Promega), according to the manufacturer’s
instructions. On the next day, the cells were treated with vehicle (DMSO)
or cycloheximide (CHX, 100 µg mL−1) over 4 h. Cell lysates were collected
and FGF21 protein was measured by ELISA as per the manufacturer in-
structions. GraphPad Prism was used to fit the data to a one-phase decay
analysis.
Measurement of Fibroblast Growth Factor 21 mRNA Stability: To deter-
mine FGF21 mRNA half-life, Huh7 cells stably expressing the A or G allele
were treated with actinomycin D (Sigma) at a concentration of 10 µg mL−1.
RNA samples were then isolated from the cells over a time course of 3 h
and then subject to qPCR. One-phase decay analysis on GraphPad Prism
was performed to determine half-life.
Polymerase Chain Reaction Microarrays: PCR microarrays were per-
formed with The TaqMan Array, Human Transcription of tRNA, Fast 96-
well which contains 28 assays for transcription of tRNA-associated genes
and 4 assays to candidate endogenous control genes. Total RNA was ex-
tracted from the cells and measured by qPCR as per the manufacturer pro-
tocols. The authors utilized three different algorithms to predict changes in
the RNA structure induced by rs838133, the RNAfold WebServer[30] (com-
pared the influence of the variant on the secondary structure of a gene),
RNAsnp[31] (provided p-values reflecting the significance of local struc-
ture base-pairing distance), and MutaRNA[32] (provided a collection of
measures and visualizations for an intuitive interpretation of the impact
of variants on the RNA secondary structure).
Bioinformatics: Each codon was analyzed relative to the codon fre-
quency within FGF21 CDS and the entire human genome. The codon us-
age frequencies of the human genome were obtained from Codon and
Codon Pair Usage Tables (CoCoPUTs).[63,64] The RSCU was defined as the
frequency of observed codons divided by the frequency expected under
the hypothesis of uniform usage of all synonymous codons for a partic-
ular amino acid.[65] RSCU values for FGF21 CDS were calculated by us-
ing R package “statanacoseq” and RSCU values for entire human genome
were calculated via utilizing CoCoPUTs. RSCU values were divided into
three categories: A) codons with RSCU values ≤0.6 (under-represented),
B) codons with RSCU values between 0.6 and 1.6 (unbiased-represented),
and C) codons with RSCU values ≥1.6 (over-represented).[66,67] Glycine
was encoded by four synonymous codons: GGG, GGA, GGC, and GGT.
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Table 1. Key resources table.
Reagent or resource Source Identifier
Antibodies
GAPDH, Mouse monoclonal antibody Abcam ab8245
FGF21, Rabbit monoclonal antibody Life Technologies MA5-32652
Secondary antibody, Goat Anti-Rabbit IgG H&L (HRP) Abcam ab6721
Secondary antibody, Goat Anti-Mouse IgG H&L (HRP) Abcam ab6789
Phospho-Akt (Ser473) (193H12) Rabbit mAb Cell Signaling 4058
Akt Antibody Rabbit mAb Cell Signaling 9272
Phospho-p44/42 MAPK (Erk1/2) Rabbit mAb Cell Signaling 4370
p44/42 MAPK (Erk1/2) Antibody Cell Signaling 9102
Bacterial and virus strains
NA
Chemicals, peptides, and recombinant proteins
Cycloheximide Sigma C7698
Actinomycin D Sigma A1410
Critical commercial assays
TaqMan Array, Human Transcription of tRNA, Fast 96-well Thermo Fisher 4418841
Human KLB/Beta Klotho Lifespan Bioscience LS-F39934
Human FAP ELISA Kit Abcam AB256404
Human FGF21 ELISA Kit R&D Systems DF2100
Automated IHC kit Leica DS9800
AHARIBO_Protein Immagina Biotechnology #AHA003_P






TaqMan SNP Genotyping Assay, human Assay ID: C-8832415_10 Thermo Fisher 4351374
Assay ID: Hs00173927_m1/FGF21 Thermo Fisher 4331182
Assay ID: Hs02786624_g1/GAPDH Thermo Fisher 4448489
Assay ID: Hs00221003_m1/FGF23 Thermo Fisher 4331182
Assay ID: Hs01653088_g1 Gene Symbol: RPLP1 Dye Thermo Fisher 4448892
Assay ID: Hs01115128_gH Gene Symbol: RPLP2 Thermo Fisher 4448892
Assay ID: Hs99999902_m1 Gene Symbol: RPLP0 Thermo Fisher 4331182
TaqMan Array, Human Transcription of tRNA, Fast 96-well Thermo Fisher 4418841
Human GAPDH primer NA Forward: AAGGTGAAGGTCGGAGTCAAG
Reverse: GGGGTCATTGATGGCAACAATA
Human TNF-A primer NA Forward: TCTCTAATCAGCCCT
Reverse: TACAACATGGGCTAC
Human CCL2 primer NA Forward:
TGC CGC CCT TCT GTG CCT G
ACA GCA GGT GAC TGG GGC AT
Human CXCL10 primer NA Forward: TGCAAGTCTATCCTGTCCGC
Reverse: TCTTTGGCTCACCGCTTTCA
Human EGR1 primer NA Forward: AGCAGCACCTTCAACCCTCAGG
Reverse: GAGTGGTTTGGCTGGGGTAACT




Graphpad Prism 7 Graphpad Graphpad
(Continued)
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Table 1. (Continued).
Reagent or resource Source Identifier
R 3.6.2. R https://www.r-project.org
GSEA 4.0.3. GSEA https://www.gsea-msigdb.org/gsea/index.jsp
Other
RNeasy Kit Qiagen 74106
qScript cDNA SuperMix Quanta Biosciences 95048
TaqMan Fast Advanced Master Mix Thermo Fisher 4444963
FuGENE HD Transfection Reagent Promega Catalog number: E2311
ON-TARGETplus Human RPLP0 siRNA smartpool Dharmacon L-010864-00-0005
ON-TARGETplus Non-targeting Pool Dharmacon D-001810-10-05
Lipofectamine RNAiMAX Transfection Reagent Invitrogen 13778150
SuperSignal West Pico PLUS Chemiluminescent and SuperSignal
West Femto Maximum Sensitivity Substrates
Life Technologies 34580, 34096
Previously published and publicly available human microarrays from
clinically defined normal, steatotic, and steatohepatitis patient livers were
obtained from the ArrayExpress database (accession E-MEXP-3291) and
analyzed for hepatic FGF21 expression correlation. Additionally, GEO
datasets GSE32504 and GSE39036 were retrieved for the differential ex-
pression genes and pathways analysis. 148 liver samples of Caucasian ori-
gin were included in these studies in which GSE32504 provided the RNA
expression data and GSE39036 provided the genotype information. R 3.6.2
was used to process the data obtained from these public datasets to gen-
erate the heatmap for hepatic FGF21 expression correlation and the vol-
cano plot for differential gene expression. GSEA was performed in GSEA
4.0.3.[68]
Transfer Ribonucleic Acid Array: cDNA synthesis for tRNA PCR array:
cDNA was synthesized by the rtStar tRNA-optimized First-Strand cDNA
Synthesis Kit (Arraystar, Inc. Rockville, MD 20850, USA, Cat#: AS-FS-004)
according to the manufacturer’s instructions. This kit used reverse tran-
scriptase at high temperature and without RNase H activity to ensure effi-
cient reverse transcription of tRNA templates with strong secondary struc-
tures in addition to a demethylation step to efficiently remove m1A, m3C,
and m1G modifications in the tRNAs which overcomes the well-known
problem that tRNAs undergo by far the greatest number of, and the most
chemically diverse post-transcriptional modifications. The kit used RNA
spike-in as an internal control for each reaction to monitor the cDNA syn-
thesis efficiency and as a reference for qPCR data comparison.
Human Transfer Ribonucleic Acid Polymerase Chain Reaction Array:
Human tRNA PCR arrays were performed with nrStar Human tRNA (Ar-
raystar, Inc. Rockville, MD 20850, USA, Cat#: AS-NR-001H-1) according
to the manufacturer’s instructions. The PCR array profiled 163 PCR-
distinguishable nuclear tRNA isodecoders and 22 PCR-distinguishable
mitochondrial tRNA species by optimized SYBR Green qPCR assays
in a PCR panel. The panel covered all the anticodons compiled in the
GtRNAdb and tRNAdb data base. 59 genes with Ct values equal to or
more than 35 were considered as not detected and were not included in
the analysis as recommended by the manufacturer data preprocessing
quality control check procedure. The PCR array included a series of
external and internal controls for correction and normalization of sample
and qPCR variabilities. These controls included:
• Three reference controls for qPCR normalization which were stably ex-
pressed small ncRNA genes (U6, 5S rRNA and 18S rRNA).
• RNA Spike-In (External Control): One external RNA spike-in mix was
added in the RNA sample prior to first strand cDNA synthesis. The RNA
spike-in control assay indicated the overall success and the efficiency of
the reaction beginning from cDNA synthesis to the final qPCR.
• Positive PCR control: One artificial DNA and the PCR primer paired to
indicate the qPCR amplification efficiency.
• gDNA Control: The control assay consisted of PCR primers for a non-
transcribed genomic region.
Patient Cohort: The study comprised 1209 Caucasian patients with
biopsy-proven MAFLD. The characteristics of the cohort and their clini-
cal and laboratory assessment are provided in Table S2, Supporting Infor-
mation. Ethics approval was obtained from the Human Research Ethics
Committees of the Western Sydney Local Health District and the Univer-
sity of Sydney. All other sites had ethics approval from their respective
ethics committees.
Genotyping: Genotyping for FGF21 rs838133 was undertaken us-
ing the TaqMan SNP genotyping allelic discrimination method (Applied
Biosystems, Foster City, CA, USA). All genotyping was blinded to clinical
variables, as previously described.[69]
Liver Histopathology: Liver biopsies were scored by an expert liver
pathologist in each participating center unaware of clinical or genetic data.
Histological scoring was based on the system proposed by Kleiner et al.[70]
Steatosis was graded from zero to three, lobular inflammation from zero to
three, and hepatocellular ballooning from zero to two. Fibrosis was staged
from zero to four with four representing cirrhosis. The Activity Score (NAS)
was calculated to quantify disease activity.[70] The interobserver agreement
between pathologists was studied previously and was excellent for steato-
sis (𝜅 = 0.85) and good for fibrosis (𝜅 = 0.78).[71]
Statistical Methods: Results were expressed as mean ± SEM (stan-
dard error of mean). The Student’s t-test or non-parametric, Wilcoxon–
Mann–Whitney U-test, or Kruskal–Wallis tests were used to compare quan-
titative data, as appropriate. 𝜒2-test and Fisher-exact tests were used for
comparison of frequency data and to evaluate the relationships between
groups and the Cochran–Armitage test was used for trend. Multivariable
logistic regression modeling was undertaken to test independent associ-
ations of the FGF21 rs838133 variant with inflammation. All tests were
two-tailed and p-values <0.05 were considered significant. Analysis was
done by SPSS or GraphPad prism.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
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